The effect of coping strategies on health –related quality of life in acromegaly patients
ConclusionOur results show that maladaptive coping styles have a substantial negative impact on psychological HRQoL in patients with acromegaly, whereas physical HRQoL is influenced to a lesser extent. Specialized training programs aimed at improving coping strategies could reduce long-term disease burden and increase HRQoL in the affected patients. (Source: Endocrine)
Source: Endocrine - April 13, 2024 Category: Endocrinology Source Type: research
Assessment of multimodal treatment options in recurrent and persistent acromegaly: a systematic review and meta-analysis
ConclusionsThe management of persistent and recurrent acromegaly optimally requires a multimodal approach. In different scenarios of refractory acromegaly based on previous treatment, secondary treatments may vary in terms of remission rate and complications. Medical agents provide considerable effectiveness as a second-line therapy for recurrent or persistent disease. In selected cases, however, reoperation still provides an opportunity for cure or freedom from medications. The findings of this study may help clinicians to prioritize varying options involved in this multifaceted decision-making process. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - April 8, 2024 Category: Cancer & Oncology Source Type: research
Double pituitary adenomas: report of two cases and systematic review of the literature
ConclusionsThe double lesion detected by surgical exploration is independently associated with a better prognosis for DPA patients. Comprehensive intraoperative exploration are crucial measures to avoid missing causative lesions. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - April 2, 2024 Category: Endocrinology Source Type: research
Tall stature and gigantism in transition age: clinical and genetic aspects—a literature review and recommendations
ConclusionThe aim of our review is to provide a practical clinical approach to recognise adolescents, potentially affected by gigantism, as early as possible. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 29, 2024 Category: Endocrinology Source Type: research
Establishing a valid cohort of patients with acromegaly by combining the National Patient Register with the Swedish Pituitary Register
ConclusionThe combination of the SPR and NPR established a valid cohort of patients diagnosed with acromegaly and increased the estimated incidence in Sweden. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 29, 2024 Category: Endocrinology Source Type: research
Tall stature and gigantism in transition age: clinical and genetic aspects—a literature review and recommendations
ConclusionThe aim of our review is to provide a practical clinical approach to recognise adolescents, potentially affected by gigantism, as early as possible. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 27, 2024 Category: Endocrinology Source Type: research
Establishing a valid cohort of patients with acromegaly by combining the National Patient Register with the Swedish Pituitary Register
ConclusionThe combination of the SPR and NPR established a valid cohort of patients diagnosed with acromegaly and increased the estimated incidence in Sweden. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 27, 2024 Category: Endocrinology Source Type: research
Trends of correlations between serum levels of growth hormone and insulin-like growth factor-I in general practice
Serum levels of growth hormone (GH) and insulin-like growth factor (IGF)-I are crucial in the diagnosis and management of GH-related diseases. However, these levels are affected by nutritional and metabolic status. To elucidate the correlations between GH and IGF-I in various conditions, a retrospective analysis was performed for adult patients in which GH levels were examined by general practitioners during the period from January 2019 to December 2021. Of 642 patients, 33 patients were diagnosed with acromegaly, 21 were diagnosed with GH deficiency (GHD), and 588 were diagnosed with non-GH-related diseases (NGRD). In con...
Source: Frontiers in Endocrinology - March 26, 2024 Category: Endocrinology Source Type: research
Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center
ConclusionPasireotide is effective and safe in the long-term. Hyperglycemia is a common event and is manageable even without insulin treatment. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 26, 2024 Category: Endocrinology Source Type: research
Validity of galactin-3 in acromegaly: comparison with traditional markers
ConclusionIn a summary, this study recommended clinicians measure serum Gal-3 as biomarkers for patients with acromegaly. In addition, the result above shed light on role of Gal-3 on acromegaly pathogenesis and might provide a therapeutic target of acromegaly patients. (Source: Irish Journal of Medical Science)
Source: Irish Journal of Medical Science - March 23, 2024 Category: General Medicine Source Type: research
Changes in multi-modality management of acromegaly in a tertiary centre over 2 decades
ConclusionThe vast majority of patients with acromegaly now have successful disease control with a multimodal approach. They reached biochemical control sooner in the most recent half of the study period. Future work should focus on those patients who are still uncontrolled and on the sequelae of the disease. (Source: Pituitary)
Source: Pituitary - March 23, 2024 Category: Endocrinology Source Type: research
Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing ’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study
ConclusionIncreasing age, HbA1c, and FPG and pre-diabetes/diabetes were associated with increased likelihood of requiring antihyperglycemic medication during pasireotide treatment. These risk factors may be used to identify those who need more vigilant monitoring to optimize outcomes during pasireotide treatment. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - March 21, 2024 Category: Endocrinology Source Type: research
A Potent Neutralizing Monoclonal Antibody to Human Growth Hormone Suppresses Insulin-Like Growth Factor-1 in female Rats
Endocrinology. 2024 Mar 19:bqae033. doi: 10.1210/endocr/bqae033. Online ahead of print.ABSTRACTAcromegaly and gigantism are disorders caused by hypersecretion of growth hormone (GH), usually from pituitary adenomas. Although somatostatin analogues (SSA), dopamine agonists and GH receptor antagonist are important therapeutic agents, all of these have issues with their effectiveness, safety, and/or convenience of use. To overcome these, we developed a GH-specific potent neutralizing mouse monoclonal antibody (mAb) named 13H02. 13H02 selectively bound to both human and monkey GH with high affinity, and strongly inhibited the ...
Source: Endocrinology - March 19, 2024 Category: Endocrinology Authors: Tomoyuki Hata Yoshikatsu Uematsu Ayumi Sugita Hisashi Adachi Sayaka Kato Maki Hirate Kei-Ichiro Ishikura Ayaka Kaku Hiroki Ohara Naoki Kojima Teisuke Takahashi Tomofumi Kurokawa Source Type: research
